The scientific committee welcomes contributions for either oral or poster presentation. THE DEADLINE HAS PASSED AND ABSTRACTS ARE NO LONGER BEING ACCEPTED. The submitted abstracts will be peer-reviewed and evaluated based on:
- Novelty and scientific quality
- Clarity of the aim and experimental design
- Relevance of the topic and the results.
Abstracts on all aspects of basic, clinical, surveillance, and management research in EDS are welcomed. A substantial number of submitted abstracts will be selected for platform presentation, the remainder of selected abstracts will be presented during an interactive poster session.
- Molecular pathogenesis of EDS and related disorders: What is the spectrum of genetic defects underlying the different forms of EDS? Have novel genes been identified since the 2017 EDS classification? What cellular events and signaling pathways drive the different manifestation of EDS, e.g. wound healing, chronic pain, joint hypermobility arterial fragility, ocular manifestations? How do they cross-talk with each other? Can we identify attractive treatment targets?
- Genotype/phenotype correlations in EDS: What new insights regarding phenotype-genotype correlations have emerged? Are they useful to guide prognostication, surveillance, preventive or treatment strategies? What are the clinical and genetic database/registry needs of the global community?
- Lessons learned from EDS animal models: What have we learned from existing animal models for EDS? What are the strengths and weaknesses of these models? Which murine models are needed to advance research in different types of EDS? How can zebrafish and other non-murine animal models advance research in EDS?
- Natural history and disease manifestations of EDS and HSD: What have we learned from natural history studies in the different forms of EDS and hypermobility syndromes? What are the risks associated with pregnancy and delivery for the different EDS subtypes? What have we learned from clinical practice on long-term outcomes in the different types of EDS?
- Genetic and environmental modifiers of EDS — phenotypic variability: What is the nature of genetic modifiers that influence phenotypic outcome in EDS? What is the influence of gender, pregnancy, and lactation on disease severity in EDS and HSD? Which environmental factors (e.g. exercise, circadian rhythm, exposures…) determine outcome?
- Insights regarding vascular manifestations in the different types of EDS and in HSD: What is the risk for life-threatening vascular manifestations in the different types of EDS? What are recommendations for surveillance and (surgical) treatment of these vascular complications? What have we learned from clinical practice? Have there been advances in identifying biomarkers that can predict arterial rupture in EDS patients?
- Insights regarding co-morbidities in the different types of EDS and HSD: What is the prevalence of the different comorbidities in the different types of EDS and in HSD (dysautonomia, mast cell activation syndrome, chronic fatigue, POTS, gastro-intestinal comorbidities, anxiety, depression, etc.)? What is the evidence for a causal relation between the different comorbidities and the underlying genetic defects? What are management strategies for these co-morbidities?
- Insights regarding pain in EDS and HSD: What do we know about the nature and the pathogenesis of pain in EDS and HSD? How can animal models advance pain research in EDS and HSD? What is the role of small fiber neuropathy? What is the role of medical and physical therapy in pain management and quality of life? What is the role of holistic treatment modalities in pain management? What are the current approaches to treatment of headache and migraine in EDS and HSD?
- Psycho-social aspects of EDS: Are there barriers to care for people with EDS? How do they manifest and what are the consequences? What are the major contributing factors? Is there a unique social/psychological profile of people with each type of EDS?
The deadline for submitting an abstract has passed.
Abstracts must be in English and submitted on-line by clicking here; you will be asked whether you want your abstract considered for oral or poster presentation, as only a limited number of oral presentations can be accepted. You will be asked to provide three keywords.
Please fill out the abstract submission form completely. This form includes:
Abstract title: should be in capital letters.
Authors: the names of the authors should be listed in the form as: last name, first name, department, institution, city, country.
Abstract body: the abstract body should contain a maximum of 350 words. The use of tables, graphs, diagrams, images, and embedded videos in the abstract submission is not allowed. Use standard abbreviations; please explain special or unusual abbreviations the first time they appear.
You will be notified automatically that your abstract application has been received. You will receive an email by 12 August 2018 if your presentation has been accepted. Authors whose abstracts have been accepted must register for the meeting and pay the registration fees before 18 August 2018. Failure to do so will result in exclusion from the program and from the abstract book.